Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) EPS (Weighted Average and Diluted) (2018 - 2025)

Corbus Pharmaceuticals Holdings has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$1.79 for Q4 2023.

  • For Q4 2023, EPS (Weighted Average and Diluted) rose 31.15% year-over-year to -$1.79; the TTM value through Dec 2023 reached -$10.35, down 1.97%, while the annual FY2024 figure was -$3.68, 64.31% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2023 was -$1.79 at Corbus Pharmaceuticals Holdings, up from -$2.27 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.03 in Q2 2019 and troughed at -$10.86 in Q4 2021.
  • A 5-year average of -$2.66 and a median of -$2.18 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 114.29% in 2019 and later tumbled 10450.0% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.03 in 2019, then plummeted by 1833.33% to -$0.52 in 2020, then plummeted by 1988.46% to -$10.86 in 2021, then soared by 76.06% to -$2.6 in 2022, then soared by 31.15% to -$1.79 in 2023.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CRBP at -$1.79 in Q4 2023, -$2.27 in Q3 2023, and -$2.05 in Q2 2023.